BioCentury
ARTICLE | Clinical News

Yosprala 325/40 regulatory update

September 19, 2016 7:00 AM UTC

FDA approved an NDA from Aralez for Yosprala 325/40 (PA32540) and Yosprala 81/40 ( PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcer...